EUVIMEDEUVIMED entdecken
Open Access

Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli

Christophe Le Terrier iD, Patrice Nordmann, Maxime Bouvier, Laurent Poirel

Antimicrobial Agents and Chemotherapy · 18.10.2023 · 67 (10)

DOI: 10.1128/aac.00547-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.10.2023. Verfasst von Christophe Le Terrier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg , Fribourg, Switzerland. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Escherichia coli. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Fribourg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli , alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against E. coli producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant E. coli , including metallo-β-lactamase producers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsEscherichia coliAnti-Bacterial Agentsbeta-LactamasesMeropenemCarbapenemsAzabicyclo CompoundsMicrobial Sensitivity Testsbeta-LactamsLactamsBorinic AcidsCarboxylic Acids

Stichwörter der Autor:innen

avibactamceftibutenfaropenemoral penemsulopenemsusceptibility testingtaniborbactamtebipenemβ-lactamase

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesMeropenemCarbapenemsAzabicyclo Compoundsfropenembeta-Lactamstebipenemsulopenem

Autor:innen und Institutionen

  • Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg , Fribourg, Switzerland.
  • Division of Intensive Care Unit, University Hospitals of Geneva , Geneva, Switzerland.
  • Swiss National Reference Center for Emerging Antibiotic Resistance , Fribourg, Switzerland.
  • University of Lausanne and University Hospital Center , Lausanne, Switzerland.

ORCID-Profile: Christophe Le Terrier

Förderung

  • University of Fribourg

Zitieren

APA

Le Terrier, C., Nordmann, P., Bouvier, M., & Poirel, L. (2023). Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli. Antimicrobial Agents and Chemotherapy, 67(10). https://doi.org/10.1128/aac.00547-23

Vancouver

Le Terrier C, Nordmann P, Bouvier M, Poirel L. Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli. Antimicrobial Agents and Chemotherapy. 2023;67(10). doi:10.1128/aac.00547-23

BibTeX
@article{LeTerrier2023,
  author = {Le Terrier, Christophe and Nordmann, Patrice and Bouvier, Maxime and Poirel, Laurent},
  title = {Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {10},
  doi = {10.1128/aac.00547-23}
}
Kostenlos starten →